Table 1 Disease characteristics of patients
From: Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer
| Â | Number of patients | Percent (%) |
|---|---|---|
Sites of extra-osseous disease | ||
   None | 64 | 58.2 |
   Liver Only | 14 | 12.7 |
   Brain Only | 1 | 0.9 |
   Lung Only | 3 | 2.7 |
   Multiple | 11 | 10.0 |
   Other | 15 | 13.6 |
   Unknown | 2 | 1.8 |
Number of bone lesions | ||
   1 | 10 | 9.1 |
   2–5 | 40 | 36.4 |
   >5 | 55 | 50.0 |
   Unknown | 5 | 4.5 |
Treatment prior to bisphosphonates | ||
   Nil | 33 | 30.0 |
   Chemotherapy +/- hormone | 31 | 28.2 |
   Hormone therapy alone | 46 | 41.8 |
Hormone therapy prior to bisphosphonates | ||
   1st line | 31 | 28.2 |
   2nd line | 19 | 17.3 |
   3rd line | 3 | 2.7 |
   Not applicable | 57 | 51.8 |
Median survival from start of bisphosphonates | Days (95% CI) | |
   All subjects | 818 (644–911) | |
   Subjects with bone metastases only | 998 (653–1342) | |
   Subjects with extra-osseous metastases | 513 (339–686) | |